Graphene Market Report 2025: Graphene Innovations Propel Lithium-Ion Battery Efficiency and Electric Vehicle Performance
Graphene Market
Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Graphene Market" report has been added to ResearchAndMarkets.com's offering.The global market for graphene is estimated to grow from $694.4 million in 2025 to reach $2.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 27.5% from 2025 through 2030.
Graphene has emerged as one of the most transformative nanomaterials due to its exceptional mechanical, electrical, thermal and optical properties. With superior electron mobility of over 200,000 cm/Vs, a tensile strength more than 100 times that of steel, and optical transparency of almost 97% (Graphenea, NanoEmi, ACS Material), graphene has enormous potential in the fields of energy, transportation, electronics, healthcare, construction, chemistry and materials. In the electronics sector, graphene is gaining momentum due to its high conductivity and flexibility, enabling the development of flexible displays, high-speed transistors and energy-efficient sensors. In addition, graphene's biocompatibility and surface functionalization potential create lucrative opportunities in biomedicine, including areas such as drug delivery systems, biosensors and antimicrobial coatings.Energy storage is another critical field, where graphene enhances lithium-ion battery and supercapacitors' performance through increased charge capacities and faster charge/discharge cycles. For instance, Sweden-based Granode Materials develops "silicon-graphene anode material" to fabricate lighter and compact lithium-ion batteries, exhibiting faster charging durability. In addition, it can hold more charge per unit of weight than other kinds of battery anodes, thus enhancing the performance of electric vehicles. In October 2024, Be Dimensional SpA, an Italian materials firm, was offered financial backing of around €20 million in venture debt finance from the European Investment Bank to increase its production of advanced graphene, strengthen Europe's industrial base and boost its international competitiveness.Other sectors also leverage graphene's high surface area and adsorption capacity for water purification and gas separation technologies. For instance, Directa Plus, an Italian supplier of graphene nanoplatelets, supplies graphene-enhanced solutions for textiles and water treatment solutions. The industrialization of graphene is being accelerated by ongoing developments in scalable synthesis techniques, including liquid-phase exfoliation and chemical vapor deposition, as well as growing funding and regulatory frameworks. Graphene is, therefore, strategically important for businesses or nations aiming to lead in advanced manufacturing, clean energy and next-generation electronics.Report ScopeThe graphene market report is segmented into product type, grade, form, production method, application, and end-use. The report covers market analysis for the U.S., Canada, Mexico, Brazil, China, Japan, India, South Korea, Germany, the U.K., Italy, France, Spain and Argentina, where the opportunity for graphene is gaining momentum in the global market. The regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA).The report includes:
Industry insights and a brief overview of the global market data for graphene
In-depth analysis of global market trends, featuring revenue data for 2024, estimated figures for 2025, including projections of CAGRs through 2030
Evaluation of the current market size and revenue growth prospects specific to graphene, accompanied by a market share analysis by country, product type, grade, form, production method, application, end use, and region
Country specific sales data and analysis for the U.S., Canada, Mexico, U.K., France, Germany, Italy, Spain, China, Japan, India, South Korea, Brazil, Argentina, Saudi Arabia, UAE, and South Africa
Key Attributes:
Report Attribute
Details
No. of Pages
126
Forecast Period
2025 - 2030
Estimated Market Value (USD) in 2025
$694.4 Million
Forecasted Market Value (USD) by 2030
$2300 Million
Compound Annual Growth Rate
27.5%
Regions Covered
Global
Key Topics Covered: Chapter 1 Executive Summary
Market Scope
Market Summary
Market Dynamics and Growth Factors
Future Trends and Development
Segmental Analysis
Regional Insights and Emerging Markets
Chapter 2 Global Graphene Market
Geographic Breakdown
Key Takeaways
Global Market for Graphene, by Region
Global Market for Graphene, by Product Type
Global Market for Graphene, by Grade
Global Market for Graphene, by Form
Global Market for Graphene, by Production Method
Global Market for Graphene, by Application
Global Market for Graphene, by End Use
Chapter 3 North American Graphene Market
Chapter 4 European Graphene Market
Chapter 5 Asia-Pacific Graphene Market
Chapter 6 South American Graphene Market
Chapter 7 The Middle East and Africa (MEA) Graphene Market
Chapter 8 Global Graphene Market, by Product Type
Key Takeaways
Graphene Oxide
Graphene Nanoplatelets
Reduced Graphene Oxide
Few-Layer Graphene
Single-Layer Graphene
Graphene Films
Other Graphene
Chapter 9 Global Graphene Market, by Grade
Key Takeaways
Industrial-Grade Graphene
Research Grade
Chapter 10 Global Graphene Market, by Form
Key Takeaways
Powder Form
Film Form
Dispersion Form
Other Forms
Chapter 11 Global Graphene Market, by Production Method
Key Takeaways
Mechanical Exfoliation
Liquid Phase Exfoliation
Chemical Vapor Deposition
Electrochemical Exfoliation
Other Production Methods
Chapter 12 Global Graphene Market, by Application
Key Takeaways
Lithium-Ion Batteries
Supercapacitors
Composites
Flexible Displays and Touchscreens
Anti-Corrosion Coatings
Biosensors
High-Frequency Transistors
Other Applications
Chapter 13 Global Graphene Market, by End Use
Key Takeaways
Energy
Transportation
Electronics
Healthcare
Chemical and Materials
Construction
Other End Uses
For more information about this report visit https://www.researchandmarkets.com/r/exf1v8
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Graphene Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Trending tickers: latest investor updates on Diageo, Palantir, Saudi Aramco, American Eagle and Hims & Hers
Diageo (DGE.L) Shares in Diageo were lower in London trading after profits at the maker of Guinness and Johnnie Walker fell by almost 30% amid a downturn in alcohol sales. The world's largest spirits firm revealed operating profits fell 27.8% to $4.33bn (£3.3bn) in the year to June 30. Sales in the 12 months to the end of June fell 0.1% to $20.2bn. Diageo's organic sales volumes rose 0.9%. It comes weeks after the group said Debra Crew had stepped down as chief executive with 'immediate effect' and by 'mutual agreement', following a decline in Diageo's share value. Interim chief executive Nik Jhangiani said: 'While macroeconomic uncertainty and the resulting pressure on consumers continues to weigh on the spirits sector, we believe in the attractive long-term fundamentals of our industry and in our ability to continue to outperform as the TBA (total beverage alcohol) landscape evolves. 'We are focused on what we can manage and control and executing at pace. 'The board and management are committed to delivering improved financial performance and stronger shareholder returns on a sustained basis.' Read more: FTSE 100 LIVE: Markets head higher again as earnings season rolls on Robinhood UK lead analyst Dan Lane said: "The bull case around Diageo was that younger people were drinking less but upping the quality, except higher inflation has meant consumers can't quite reach the top shelf anymore and are seemingly trading down as well as slowing down. "Diageo was banking on its premium portfolio so, with that strategy on the rocks, we need to hear a lot more about plans for its cabinet of standard household names now too. The fact that profits and margins have struggled so much, even at the height of Guinness's popularity, has quite rightly sounded alarm bells. "The past few years have seriously tarnished Diageo's all-weather reputation. Swapping its 'something for everyone' brand stable for premium bottles was a risk that clearly paid off until inflation started to bite. We're now seeing what happens when you pin your hopes on one strategy and, crucially, don't fix the roof while the sun's still shining." Palantir (PLTR) Shares in Palantir were almost 6% higher in pre-market trading as the AI software provider topped Wall Street estimates, surpassing $1bn in quarterly revenue for the first time. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25bn and was up 48% year-over-year. US commercial revenue jumped 93% from the previous year to $306m, while US government revenue grew 53% to $426m. Overall US revenue was up 68% to $733m. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." The Denver-based firm, which sells software to centralise, manage and analyse large amounts of data, raised its revenue guidance to $4.14bn to $4.15bn for the full year. It raised its US commercial revenue guidance to in excess of $1.302bn, representing a growth rate of at least 85%. Saudi Aramco ( Shares in Saudi Aramco edged higher on Tuesday, despite the state-controlled oil giant reporting a decline in second-quarter revenues. The world's largest oil company declared an adjusted net income of 92.04bn Saudi riyal (£18.5bn/$24.5bn) over the three months to the end of June. The result compares with a forecast of adjusted net income of $23.7 billion, according to an analyst survey estimate supplied by the company. However, revenues for the three months to the end of June fell to 378.83bn riyals, down from 425.71bn riyals during the same period last year. 'Market fundamentals remain strong and we anticipate oil demand in the second half of 2025 to be more than two million barrels per day higher than the first half,' Aramco CEO Amin Nasser said in a statement accompanying the results. Read more: BP beats on profit, raises dividend as oil major strives to rebuild investor confidence The company is expected to benefit from a production rebound in the months ahead, as Saudi Arabia and a coalition of OPEC and non-OPEC producers continue to phase out 2.2 million barrels per day in voluntary supply cuts. The final stage of this unwinding is due in September. According to the latest Monthly Oil Market Report from OPEC, Saudi Arabia produced 9.356 million barrels per day in June, based on independent analyst estimates. American Eagle Outfitters (AEO) Shares in American Eagle Outfitters were higher in pre-market trading and closed 23% higher on Monday after US president Donald Trump complimented the retailer's marketing campaign with actress Sydney Sweeney. "Sydney Sweeney, a registered Republican, has the 'HOTTEST' ad out there," Trump wrote in a post on Truth Social, the social media platform he owns. "It's for American Eagle, and the jeans are 'flying off the shelves.' Go get 'em Sydney!" The campaign, which features the slogan 'Sydney Sweeney has great jeans,' has drawn criticism from some commentators, who have accused the company of using a double entendre. Critics argue the slogan refers not to denim but to Sweeney's appearance — particularly her blonde hair and blue eyes — suggesting a coded message about genetic traits. American Eagle responded to the accusations on Sunday in a post on its Instagram page: "'Sydney Sweeney has great jeans' is and always was about the jeans. Her jeans. Her story." The marketing boost comes at a critical time for the US apparel retailer, which has faced sluggish performance amid a challenging retail environment. Earlier this year, American Eagle announced a $75m write-down in spring and summer merchandise and withdrew its full-year guidance, citing slow sales, aggressive discounting and macroeconomic uncertainty. In its May earnings update, the company said it expected second-quarter revenue to decline 5%, with comparable sales down 3% and gross margins under pressure. Operating income for the quarter was forecast to fall between $40m and $45m. Hims & Hers (HIMS) Shares in Him & Hers Health plunged 14% ahead of the US opening bell after the telehealth company reported second-quarter results that fell short of Wall Street's revenue expectations, despite strong year-on-year growth. Revenue rose 73% to $546.9m, up from $315.6m during the same period last year, according to a company release. Net income for the quarter came in at $42.5m, or 17 cents per share, an increase from $13.3m, or 6 cents per share, a year earlier. However, the top-line growth failed to impress investors, with revenue figures coming in below consensus estimates. The company's third-quarter guidance also disappointed. Hims & Hers said it expects revenue between $570m and $590m, compared with analyst expectations of $583m. The company projected adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) for the third quarter to fall in the range of $60m to $70m, below the $77.1m forecast by analysts surveyed by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Registrations of new cars down by 5% in July as drivers delay EV purchases
Registrations of new cars down by 5% in July as drivers delay EV purchases Registrations of new cars stalled in July as many drivers delayed purchases of electric vehicles (EVs) until Government grants are rolled out. The Society of Motor Manufacturers and Traders (SMMT) said 140,154 new cars were registered last month, down 5% from 147,517 during July 2024. Battery electric vehicles (Bevs) held a 21.3% share of the new car market last month. At least 28% of new cars sold by each manufacturer in the UK this year are required to be zero emission – which generally means pure electric – under the Government's zero emission vehicle mandate. The first electric car models eligible for new Government grants were announced on Tuesday. Drivers will be able to save £1,500 with the purchase of new Citroen e-C3, e-C4, e-C5 and e-Berlingo cars. These are the first models approved under the new £650 million electric car grant. The scheme will enable motorists purchasing a new electric car to save either £1,500 or £3,750, depending on the vehicle's sustainability. SMMT chief executive Mike Hawes said: 'July's dip shows yet again the new car market's sensitivity to external factors, and the pressing need for consumer certainty. 'Confirming which models qualify for the new EV grant, alongside compelling manufacturer discounts on a huge choice of exciting new vehicles, should send a strong signal to buyers that now is the time to switch. 'That would mean increased demand for the rest of this year and into next, which is good news for the industry, car buyers and our environmental ambitions.' The SMMT slightly upgraded its forecast for full-year new car registrations, to 1.9 million. Registrations in 2024 reached 1.95 million. Bevs are forecast to hold a full-year market share of 23.8%. Ian Plummer, commercial director at online vehicle marketplace Auto Trader, said the grant has provided a 'much-needed boost' for consumer interest in new electric cars, with EV consideration up 10 percentage points on Auto Trader. But the unveiling of the initiative on July 14 explains why it was a 'slow' month for sales as buyers 'wait to see just which models will get what level of grant'. He added that discounts – either through the grant or by brands cutting prices themselves – will 'trickle through to EV sales in the coming months'.
Yahoo
14 minutes ago
- Yahoo
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
STOCKHOLM, SE / / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract about the preclinical project TrkA-NAM ACD137 against osteoarthritis and other severe pain conditions has been accepted for presentation at the international pain conference NeuPSIG 2025, to be held in Berlin, Germany, September 4-6. The abstract, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA , will be presented at NeuPSIG 2025 by Märta Segerdal, Head of Development and Chief Medical Officer at AlzeCure Pharma. Co-authors are Pontus Forsell, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Gunnar Nordvall. The results show that the lead drug candidate in the project, ACD137, has potent analgesic effects in several different preclinical pain models. The analgesic effect of ACD137 in the study was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. ACD137 achieves its effect by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain. These positive preclinical data in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with ACD137 and further underline its broad applicability in various severe pain conditions, including osteoarthritis. "These data demonstrate that our drug candidate ACD137 is a highly potent and selective TrkA-NAM that exhibits significant analgesic effects in relevant preclinical animal models. Furthermore, this small molecule TrkA-NAM has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action, while maintaining analgesic efficacy," said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure Pharma. "The project is based on a mechanism with strong validation, both preclinically and clinically. The results we have for TrkA-NAM in pain are promising, and the fact that we also have anti-inflammatory effects with our substance opens up for broader application. The fact that this is also a mechanism that is not linked to the side effects and addiction problems observed with opioids and antibodies is of course also important for a potential future approval," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster will be available on AlzeCure's website after the presentation ( For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit About TrkA-NAMThe TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically and provides a promising alternative to new analgesics without the side effects and addiction problems observed with opioids. Substances developed in the project have recently been shown to also have anti-inflammatory properties. For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain. The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 400 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field. Read more about TrkA-NAM on our homepage. Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
